Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines.

A series of 7-aryl- and 7-hetaryl-7-deazaadenosines was prepared by the cross-coupling reactions of unprotected or protected 7-iodo-7-deazaadenosines with (het)arylboronic acids, stannanes, or zinc halides. Nucleosides bearing 5-membered heterocycles at the position 7 exerted potent in vitro antiproliferative effects against a broad panel of hematological and solid tumor cell lines. Cell cycle analysis indicated profound inhibition of RNA synthesis and induction of apoptosis in treated cells. Intracellular conversion to triphosphates has been detected with active compounds. The triphosphate metabolites showed only a weak inhibitory effect on human RNA polymerase II, suggesting potentially other mechanisms for the inhibition of RNA synthesis and quick onset of apoptosis. Initial in vivo evaluation demonstrated an effect of 7-(2-thienyl)-7-deazaadenine ribonucleoside on the survival rate in syngeneic P388D1 mouse leukemia model.

[1]  R. Pohl,et al.  Phosphoramidate pronucleotides of cytostatic 6-aryl-7-deazapurine ribonucleosides. , 2011, Bioorganic & medicinal chemistry.

[2]  C. Cameron,et al.  Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses. , 2010, Journal of medicinal chemistry.

[3]  Helena Zábranská,et al.  CycloSal‐phosphate Pronucleotides of Cytostatic 6‐(Het)aryl‐7‐deazapurine Ribonucleosides: Synthesis, Cytostatic Activity, and Inhibition of Adenosine Kinases , 2010, ChemMedChem.

[4]  R. Pohl,et al.  Direct polymerase synthesis of reactive aldehyde-functionalized DNA and its conjugation and staining with hydrazines. , 2010, Angewandte Chemie.

[5]  R. Pohl,et al.  6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. , 2010, Journal of medicinal chemistry.

[6]  William A. Lee,et al.  Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. , 2009, Molecular pharmaceutics.

[7]  W. Parker.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. , 2009, Chemical reviews.

[8]  C. K. Chu,et al.  Structure-activity relationships of 7-deaza-6-benzylthioinosine analogues as ligands of Toxoplasma gondii adenosine kinase. , 2008, Journal of medicinal chemistry.

[9]  C. Galmarini,et al.  Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. , 2008, Current medicinal chemistry.

[10]  M. Fojta,et al.  Aminophenyl- and nitrophenyl-labeled nucleoside triphosphates: synthesis, enzymatic incorporation, and electrochemical detection. , 2008, Angewandte Chemie.

[11]  P. Džubák,et al.  Synthesis and cytotoxic activity of various 5-[alkoxy-(4-nitro-phenyl)-methyl]-uracils in their racemic form. , 2007, Bioorganic & medicinal chemistry letters.

[12]  F. Seela,et al.  7-Functionalized 7-deazapurine β-d and β-l-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo[2,3-d]pyrimidines with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-d or β-l-ribofuranose , 2007 .

[13]  P. Čapek,et al.  An efficient method for the construction of functionalized DNA bearing amino acid groups through cross-coupling reactions of nucleoside triphosphates followed by primer extension or PCR. , 2007, Chemistry.

[14]  A. Ray,et al.  Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  P. Fischer,et al.  4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. , 2006, Journal of medicinal chemistry.

[16]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[17]  C. Galmarini,et al.  Recent developments to improve the efficacy of cytotoxic nucleoside analogues. , 2006, Recent patents on anti-cancer drug discovery.

[18]  P. Čapek,et al.  Cross-coupling reactions of unprotected halopurine bases, nucleosides, nucleotides and nucleoside triphosphates with 4-boronophenylalanine in water. Synthesis of (purin-8-yl)- and (purin-6-yl)phenylalanines. , 2006, Organic & biomolecular chemistry.

[19]  M. Erion,et al.  Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues. , 2005, Journal of Medicinal Chemistry.

[20]  T Robak,et al.  Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. , 2005, Current cancer drug targets.

[21]  M. Otto,et al.  Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. , 2005, Journal of medicinal chemistry.

[22]  B. Ugarkar,et al.  Adenosine kinase inhibitors. 4. 6,8-Disubstituted purine nucleoside derivatives. Synthesis, conformation, and enzyme inhibition. , 2005, Journal of medicinal chemistry.

[23]  Giovanni Migliaccio,et al.  A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties , 2004, Antimicrobial Agents and Chemotherapy.

[24]  P. D. Cook,et al.  Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. , 2004, Journal of medicinal chemistry.

[25]  Yoshinori Yamamoto,et al.  Copper‐Catalyzed Synthesis of N‐Unsubstituted 1,2,3‐Triazoles from Nonactivated Terminal Alkynes , 2004 .

[26]  Quanlai Song,et al.  Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. , 2004, Journal of medicinal chemistry.

[27]  M. Erion,et al.  Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of l-lyxofuranosyl nucleosides. , 2003, Journal of medicinal chemistry.

[28]  P. Gannett,et al.  Efficient one-step Suzuki arylation of unprotected halonucleosides, using water-soluble palladium catalysts. , 2003, The Journal of organic chemistry.

[29]  C. Dumontet,et al.  Drug resistance to cytotoxic nucleoside analogues. , 2003, Current drug targets.

[30]  J. Mackey,et al.  Nucleoside analogues and nucleobases in cancer treatment. , 2002, The Lancet. Oncology.

[31]  P. Džubák,et al.  In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells. , 2002, Neoplasma.

[32]  S. Johnson,et al.  Nucleoside analogues in the treatment of haematological malignancies , 2001, Expert opinion on pharmacotherapy.

[33]  Michal Hocek,et al.  Cytostatic 6-Arylpurine Nucleosides III. Synthesis and Structure-Activity Relationship Study in Cytostatic Activity of 6-Aryl-, 6-Hetaryl- and 6-Benzylpurine Ribonucleosides , 2001 .

[34]  S. Johnson,et al.  Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies , 2000 .

[35]  M. Erion,et al.  Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. , 2000, Journal of medicinal chemistry.

[36]  Michal Hocek,et al.  Synthesis and cytostatic activity of substituted 6-phenylpurine bases and nucleosides: application of the Suzuki-Miyaura cross-coupling reactions of 6-chloropurine derivatives with phenylboronic acids. , 2000, Journal of medicinal chemistry.

[37]  A. Reitz,et al.  Synthesis of 4-Substituted Imidazoles via Palladium-Catalyzed Cross-Coupling Reactions , 1998 .

[38]  M. Strnad,et al.  Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine. , 1997, Anti-cancer drugs.

[39]  W. Plunkett,et al.  Metabolism and action of purine nucleoside analogs. , 1991, Pharmacology & therapeutics.

[40]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[41]  A. Bell,et al.  A synthesis of 2- and 4(5)-(2-pyridinyl)imidazoles by palladium-catalysed cross-coupling reactions , 1988 .

[42]  R. K. Robins,et al.  A facile synthesis of tubercidin and related 7-deazapurine nucleosides via the stereospecific sodium salt glycosylation procedure , 1987 .

[43]  R. K. Robins,et al.  Purine analogs and related nucleosides and nucleotides as antitumor agents , 1985, Medicinal research reviews.

[44]  E. De Clercq,et al.  Antiviral activity of C-5 substituted tubercidin analogues. , 1984, Journal of medicinal chemistry.

[45]  A. Cook,et al.  Synthesis of the Natural Product 5'-Deoxy-5-iodotubercidin and Related Halogenated Analogs , 1984 .

[46]  R. K. Robins,et al.  Pyrrolopyrimidine nucleosides. 3. The total synthesis of toyocamycin, sangivamycin, tubercidin, and related derivatives. , 1969, Journal of the American Chemical Society.

[47]  E. Reich,et al.  BIOLOGICAL AND BIOCHEMICAL PROPERTIES OF THE ANALOGUE ANTIBIOTIC TUBERCIDIN. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Suzuki,et al.  A new antibiotic, tubercidin. , 1957, The Journal of antibiotics.